Nivolumab-induced cholangitic liver disease: A novel form of serious liver injury

Annals of Oncology

Volumn 28, Issue 3, 2017, Pages 671-672

  Gelsomino, F ^a   Vitale, G ^a   D'Errico, A ^a   Bertuzzi, C ^a   Andreone, P ^a   Ardizzoni, A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; HLA DR11 ANTIGEN; METHYLPREDNISOLONE; NIVOLUMAB; URSODEOXYCHOLIC ACID; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

AGED; AUTOIMMUNE HEPATITIS; CASE REPORT; CHOLANGITIS; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAUNDICE; LETTER; LIVER BIOPSY; LIVER TOXICITY; MALE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PRURITUS; CHEMICALLY INDUCED; LUNG TUMOR; TOXIC HEPATITIS;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHOLANGITIS; HUMANS; LUNG NEOPLASMS; MALE;

EID: 85018258494     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw649     Document Type: Letter

References (5)

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264.
2. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl JMed 2015; 373: 123-135.
3. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-1639.
4. Clinical Practice Guidelines EASL. Autoimmune hepatitis. European Association for the Study of the Liver. J Hepatol 2015; 63: 971-1004.
5. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. European Association for the Study of the Liver. J Hepatol 2009; 51: 237-267.